Eli Lilly to Acquire Seattle-Area Biotech Curevo for $1.5 Billion
Eli Lilly is set to acquire Seattle-area biotech Curevo Vaccine for up to $1.5 billion to bolster its infectious disease portfolio. The deal centers on Curevo's Phase 3-ready shingles vaccine candidate, amezosvatein, which demonstrated a more than 50% reduction in side effects during Phase 2 studies, aiming to boost vaccination rates among older adults.
Pharmaceutical giant Eli Lilly has announced its definitive agreement to acquire Bothell, Washington-based biotech firm Curevo Vaccine in a deal potentially worth up to $1.5 billion in cash. The acquisition, unveiled this week, strategically targets Curevo’s promising next-generation shingles vaccine candidate, amezosvatein, with the aim of significantly enhancing patient tolerability and boosting crucial vaccination rates among the elderly population. This substantial investment underscores Lilly's aggressive expansion into the infectious disease sector.
A Bet on Better Tolerability
The financial terms of the agreement comprise an initial upfront payment alongside a contingent milestone payment, reflecting Lilly's strong belief in the potential of Curevo's innovative therapy. At the core of the deal is amezosvatein, a vaccine nearing Phase 3 clinical trials, designed to offer a superior alternative to current market options. Its primary differentiation lies in its ability to provide robust protection against shingles while substantially reducing the commonly reported adverse effects.
Shingles, a reactivation of the chickenpox virus, afflicts approximately one in three adults in the U.S. over their lifetime, often leading to debilitating chronic nerve pain and other severe complications. While highly effective vaccines like GlaxoSmithKline's Shingrix have been available since 2017 and are widely recommended, patient reluctance to complete the full vaccination regimen due to side effects remains a persistent public health challenge. Curevo’s Phase 2 head-to-head study notably demonstrated that amezosvatein reduced reported side effects—including fatigue, chills, and injection-site pain—by more than 50%, a critical improvement for patient adherence.
Strategic Expansion and Broader Health Impact
This acquisition is a cornerstone of Eli Lilly's broader initiative this week, involving three separate deals aimed at significantly strengthening its infectious disease pipeline. Daniel Skovronsky, Lilly’s Chief Scientific and Product Officer, highlighted the growing scientific understanding linking shingles prevention to reduced risks of stroke and even potential benefits in lowering dementia risk. Skovronsky stated that a vaccine offering "meaningfully better tolerated" side effects could vastly extend the reach of shingles prevention to a wider, more vulnerable demographic.
Curevo CEO George Simeon echoed this focus, emphasizing the company's commitment to "improving the shingles immunization experience so more adults can benefit from protection against shingles, a serious disease with significant risk for long-term impairment of healthy living." The collaboration with Eli Lilly, a pharmaceutical powerhouse with vast global resources, is expected to dramatically accelerate the development and eventual market launch of amezosvatein, pushing it quickly through late-stage development.
Curevo's Genesis and Growth
Curevo Vaccine was initially established in 2018 as a strategic alliance between GC Pharma, the Mogam Institute for Biomedical Research based in Seoul, and Seattle's Access to Advanced Health Institute. The Bothell-based biotech successfully raised $110 million in venture funding just last year, attracting capital from prominent investors such as Medicxi, OrbiMed, HBM Healthcare Investments, Sanofi Ventures, RA Capital Management, Janus Henderson Investors, Adjuvant Capital, and its founding investor, GC Biopharma. This strong investor backing and innovative vaccine technology positions amezosvatein as a significant contender in the global vaccine market, now bolstered by Lilly’s formidable capabilities.
FAQ
Q: What is the main reason Eli Lilly is acquiring Curevo Vaccine? A: Eli Lilly is acquiring Curevo Vaccine primarily for its next-generation shingles vaccine candidate, amezosvatein, which aims to provide effective shingles prevention with significantly fewer side effects compared to existing vaccines, thereby increasing vaccination rates among older adults.
Q: How much is the acquisition worth? A: The deal is valued at up to $1.5 billion in cash, consisting of an initial upfront payment and a contingent payment based on future milestones.
Q: What are the potential broader health implications of Curevo's vaccine? A: Beyond preventing shingles, emerging research suggests a link between shingles infection and increased stroke risk, and conversely, shingles vaccination may potentially reduce the risk of dementia. A more tolerable vaccine could therefore offer widespread benefits for public health.
Related articles
Pentagon Halts 155 Wind Projects in 24 States Over Drone Fears
The Pentagon has frozen permitting for 155 wind projects across 24 states for nearly a year, citing concerns that drones can hide within wind farms. This impacts 44 gigawatts of capacity and has cost developers $2 billion. The wind industry claims the freeze is politically motivated and has filed a lawsuit.
in-depth: Chewy Promo Codes: $20 Off July 2026: coupons — Key Details
Pet owners can find substantial savings at Chewy in July 2026. New customers get $20 off first orders (code WELCOME) and free shipping. Existing users benefit from exclusive deals, Autoship discounts, and a Chewy+ membership for ongoing perks and rewards.
Kalshi says it caught Trump’s teleprompter operator insider trading
Prediction market platform Kalshi has accused Donald Trump's teleprompter operator, Gabriel Perez, of insider trading, alleging he used advance knowledge of Trump's speeches to win over $100,000. Kalshi flagged the activity and referred it to the CFTC. While federal prosecutors declined a criminal case, a settlement is being discussed.
AI-powered travel agency Fora hits unicorn status, raises $60M
Fora, the innovative AI-powered travel agency, has officially joined the ranks of billion-dollar companies, announcing a $60 million Series D funding round that solidifies its unicorn status. The capital injection, led
in-depth: 11 Best Sleeping Bags (2026): Ultralight, Warm Weather, for
A comprehensive guide to the best sleeping bags for 2026 has been released, featuring expert-tested options for every outdoor adventure. From ultralight designs to comfy car camping bags and kid-specific models, this updated selection helps adventurers find their perfect sleep system for warmth and comfort.
Applied Computing wants to give oil and gas operators an AI model for
Applied Computing, a London-based startup, has secured $20 million in Series A funding to advance its foundation AI model, Orbital, for the oil, gas, and petrochemical industry. Orbital aims to integrate disparate data sources—sensor readings, engineering data, and physics models—to provide real-time operational insights, drastically reducing investigation times and enhancing efficiency. The company plans to use the capital for international expansion, hiring, and new client deployments, building on its rapid growth and strategic partnerships with industry giants like KBR.